City of Hope Cohort

We reviewed a molecular database from a single center (City of Hope [COH]) to identify 338 patients with mCRC treated between years 2015 and 2018. Only cases with mCRC with tissue CGP (FoundationOne or FoundationOne CDx) were included in the analysis. Tumors with RAS amplification were identified and were linked to deidentified patient characteristics and patient clinical response to anti‐EGFR therapy (n = 6; see CONSORT diagram in supplemental online Fig. 2). The study was approved by the institutional review board of the COH National Comprehensive Cancer Center (14361).